The biomarker assay will operate on a small blood-testing device for home-use, named Trace™, which enables patients to retrieve information about the level of medicine and possibly neutralising antibodies within 15 minutes from home, all by themselves.
The project will make a significant contribution to the development of personalised medicine in patients treated with biologic medicine by enabling a more accurate dispensation of medicine. The impact will be that physicians and patients may optimise patients’ medical treatment, thereby ensuring a more optimal use of healthcare resources.
The total funding for the project is € 1,348,000, which roughly equals kr. 10,000,000
The Parker Institutes share is € 190,000, which roughly equals kr. 1,400,000
See further details about the Trace™ platform at www.atonomics.com
See further details in the official press release from Innovation Fund Denmark at www.innovationsfonden.dk/da/nyhed/eurostars-19-danske-projekter-slap-igennem-naaleoejet"